June 16th, 2020
SDARTs faculty member, Robert W. Alexander, MD, DDS, is the Principle Investigator on a first-in-human clinical trial to treat post-COVID 19 survivors with AD cSVF.
Many moderate to severe post-COVID 19 survivors experience compromised lung function. As a proposed solution, adipose-derived cellular stromal vascular fraction (AD cSVF) may be effective in reversing residual damage to the lungs and gas exchange functions.
This article was published in Stem Cell Research.
Overview_COVID-19_Lung_Damage_cSVF_Final_6-10-20_Stem_Cell_Res
.pdf
Download PDF • 500KB
Want to learn more from Dr. Alexander?
Visit the SDARTs Online Learning Center >